HK Stock Connect Insight | HENLIUS (02696.HK) First-Half Net Profit Up 10.3% YoY, Included in Stock Connect from September 7

NewTimeSpace News: On October 29, 2026, HENLIUS closed at HKD 49.92, down 1.34% for the day, with turnover of HKD 20.2259 million.

According to publicly available information, HENLIUS listed on the Main Board of HKEX on September 25, 2019 at an offer price of HKD 49.60. In February 2026, the company completed the full circulation of its H shares, raising the free float ratio of its H shares to 63.68%. In August 2026, the company was included in the MSCI China Small Cap Index.

Over the past 52 weeks, the share price has ranged from a high of HKD 87.10 to a low of HKD 47.62. As of October 29, 2026, the stock closed at HKD 49.92, about 42.69% below its 52-week high. Since its inclusion in Stock Connect, the share price has fallen from HKD 65.55 at the close on September 7, 2026 to HKD 49.92, a cumulative decline of about 23.8%.

Hang Seng Indexes Company announced on August 21, 2026 the results of its quarterly review of the Hang Seng Index series for the period ended June 30, 2026, under which HENLIUS was included in the Hang Seng Composite Index, with the constituent change effective on September 7, 2026. The Shanghai and Shenzhen stock exchanges subsequently adjusted their respective lists of eligible securities under Stock Connect, and the company's H shares were included in the list of eligible securities for Stock Connect with effect from September 7, 2026.

Founded in 2010 and headquartered in Shanghai, HENLIUS is an international innovative biopharmaceutical company that listed on HKEX in September 2019. As of early 2026, the company had 10 products approved for marketing in more than 60 countries and regions, of which 4 were approved by the US FDA and 5 by the European Union. Its core product HANSIZHUANG (serplulimab), known as the "H drug", is the world's first approved anti-PD-1 monoclonal antibody for the first-line treatment of small cell lung cancer and has been approved in 50 markets globally.

On the financial front, the company's revenue for the first half of 2026 was RMB 3.588 billion, up 27.3% year on year, and net profit was RMB 430 million, up 10.3% year on year. Of the total, global product sales amounted to RMB 2.939 billion, up 14.9% year on year, and overseas product sales amounted to RMB 105 million, up 159.4% year on year. R&D investment was RMB 1.451 billion, up 45.7% year on year.